Pediatric Epilepsy Study
Public ClinicalTrials.gov record NCT00050947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures.
Study identification
- NCT ID
- NCT00050947
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- oxcarbazepine Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Month to 16 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2002
- Primary completion
- Jan 31, 2004
- Completion
- Jan 31, 2004
- Last update posted
- Nov 22, 2011
2002 – 2004
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Mobile | Alabama | 36693 | — |
| Not listed | Madera | California | 93638 | — |
| Not listed | Orange | California | 92868 | — |
| Not listed | Denver | Colorado | 80218 | — |
| Not listed | Miami | Florida | 33155 | — |
| Not listed | Tampa | Florida | 33607 | — |
| Not listed | Atlanta | Georgia | 30342 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Duluth | Minnesota | 55805 | — |
| Not listed | Saint Paul | Minnesota | 55102 | — |
| Not listed | Chesterfields | Missouri | 63017 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Buffalo | New York | 14222 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | Raleigh | North Carolina | 27607 | — |
| Not listed | Akron | Ohio | 44308 | — |
| Not listed | Cincinnati | Ohio | 45229 | — |
| Not listed | Cleveland | Ohio | 44106 | — |
| Not listed | Portland | Oregon | 97201 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213 | — |
| Not listed | Spartenberg | South Carolina | 29303 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00050947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 22, 2011 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00050947 live on ClinicalTrials.gov.